Pharmaceutical

Novan announced new preclinical data for two studies with SB414 treating inflammatory skin diseases will be showcased Society for Investigative Dermatology conference.

Novan (NASDAQ:NOVN) announced new preclinical data for two studies with SB414 treating inflammatory skin diseases will be showcased at the annual Society for Investigative Dermatology conference.
As quoted in the press release:

In a psoriasis mouse model, SB414 significantly (p<0.05) reduced composite psoriasis scores and also inhibited the production of pro-inflammatory cytokines, including interleukin-17, or IL-17a and IL-17f. Additionally, in two in vivo models that assess critical components of atopic dermatitis disease pathology, SB414 displayed potent anti-staphylococcal activity and dose-dependent inhibition of inflammation comparable to betamethasone, a mid-potency corticosteroid used to treat eczema patients.

“Both psoriasis and atopic dermatitis patients are in need of new topical therapeutic options,” said Alan Menter, M.D., program director of dermatology residency and chair of dermatology for Baylor University, and dermatologist at Texas Dermatology Associates, P.A. “I am specifically intrigued by SB414’s effect on the proven psoriatic pathway IL23/IL17. The majority of new drugs for psoriasis over the past 12 years have been limited to systemic and biologic therapies. Approximately six million people in the United States, or 80% of all psoriasis sufferers, with mild to moderate disease have been treated purely with topical agents and have yet to benefit from our deeper understanding of the pathophysiology of the disease. These preclinical results give hope that there may be a therapeutically valuable, novel topical treatment that downregulates many of the key cytokines in the immunological cascade of psoriasis.”

Novan plans to submit an Investigational New Drug application, or IND, to the U.S. Food and Drug Administration, or FDA, for SB414 in the second quarter of 2017 and initiate clinical development of the nitric oxide-releasing cream with a Phase 2 proof-of-concept trial in patients with mild-to-moderate psoriasis.

Click here to read the full press release.

Source: globenewswire.com

MARKETS

Markets
TSX19078.64-144.10
TSXV626.34-18.57
DOW31029.31+82.32
S&P 5003818.83-2.72
NASD11177.89-3.65
ASX6763.60+57.60

COMMODITIES

Commodities
Gold1818.55-0.02
Silver20.76-0.06
Copper3.77-0.01
Palladium1965.50+96.50
Platinum919.00+9.00
Oil109.43-2.33
Heating Oil3.95-0.16
Natural Gas6.41-0.16

DOWNLOAD FREE REPORTS

×